Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were lower after the close on Monday, as losses in the Oil & Gas, Consumer Services and Technology sectors led shares lower. At the close in NYSE, the...
By Geoffrey Smith Investing.com -- U.S. stocks opened lower on Monday as risk appetite dried up ahead of the Federal Reserve's policy-setting meeting that takes place on Tuesday...
By Catherine ReynoldsInvesting.com -- Arena Pharmaceuticals Inc (NASDAQ:ARNA) shares jumped 82% on Monday after Pfizer Inc (NYSE:PFE) announced plans to buy the drug developer...
Equity index futures are pointing slightly higher on Monday morning as investors appear to be a little tentative ahead of the Fed meeting later this week. Friday’s Consumer...
Broader markets are close to record highs. Year-to-date, the Dow Jones Industrial Average, the S&P 500 and the NASDAQ 100 are up around 11.5%, 11.6% and 8.2%,...
Apache Corporation (NYSE:APA) in the oil sector is still hanging in there. On Thursday, it popped 33 cents, or 2.38%, to 14.22,...
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company’s investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn’s disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Buy | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Buy | Buy | Buy | Strong Buy | Strong Buy |
| Summary | Neutral | Strong Buy | Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 137.79 | 138.41 | 136.30 | +1.23 | +0.90% | 3.65M | NYSE | |||
| 64.88 | 65.22 | 64.76 | -0.15 | -0.23% | 8.13M | NYSE | |||
| 49.27 | 49.86 | 49.25 | -0.59 | -1.18% | 13.46M | NYSE | |||
| 7.68 | 7.99 | 7.63 | -0.41 | -5.01% | 5.43M | NYSE | |||
| 112.99 | 113.37 | 111.78 | -0.77 | -0.68% | 610.49K | NYSE | |||
| 23.41 | 23.70 | 22.87 | +0.36 | +1.56% | 12.64M | NYSE | |||
| 23.08 | 30.00 | 22.50 | +2.43 | +11.77% | 245.12M | NASDAQ | |||
| 1.90 | 1.94 | 1.86 | -0.030 | -1.55% | 170.89K | NYSE | |||
| 266.82 | 267.97 | 265.58 | +0.53 | +0.20% | 1.69M | NYSE | |||
| 2.45 | 2.51 | 2.41 | -0.050 | -2.00% | 359.10K | NASDAQ | |||
| 111.62 | 112.81 | 109.27 | -2.34 | -2.05% | 546.79K | NASDAQ | |||
| 38.20 | 38.80 | 38.15 | -0.63 | -1.62% | 5.90M | NASDAQ | |||
| 69.11 | 69.85 | 68.72 | -1.03 | -1.47% | 2.06M | NYSE | |||
| 158.00 | 167.62 | 157.68 | -9.96 | -5.93% | 5.32M | NASDAQ | |||
| 147.94 | 148.12 | 146.34 | +0.82 | +0.56% | 732.87K | NYSE |